<p>(A-B) HepG2 cells were transfected without (Empty) or with V5-tagged PCSK9 full-length (FL), ΔCTD, CTD alone or PCSK9-TM-CT-Lamp1 chimeras (FL, F379A, ΔCTD, CTD) or Timp1-TM-CT-Lamp1 (herein used as control). Forty-eight hours post-transfection, LDLR, PCSK9 and β-actin (loading control) protein levels were analyzed by IB. Data are representative of at least three independent experiments</p
<p>(A and B) Western blot showing APLP2, PCSK9, or Transferrin receptor (TFNR) levels in input fract...
The proprotein convertase PCSK9, a target for the treatment of hypercholesterolemia, is a negative r...
The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is involved in the post-transcription...
<p><b>A</b>) PCSK9 transfection. HEK293 cells were transfected with PCSK9-V5 or empty control pIRES-...
<p>(A) HepG2 cells transfected with LDLR-EGFP were incubated 5h with conditioned media obtained from...
<p><b>A</b>) Chimeric PCSK9 constructs. Schematic representation of PCSK9 and its CHRD coupled to th...
<p><b>A</b>) Generation of chimeric truncated LDLR-V5 constructs. Schematic representation of the LD...
<p><b>A</b>) and <b>C</b>) Secreted Fc (human IgG1 fragment crystallizable region), Fcpro (Fc fused ...
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) post-transcriptionally degrades th...
PCSK9 is a secreted ligand and negative post-translational regulator of low-density lipoprotein rece...
The discovery that proprotein convertase subtilisin/kexin type 9 (PCSK9) mediates degradation of low...
<p>(A) PCSK9 further reduced LPS uptake in Ldlr-/- cells. Primary hepatocytes were isolated from Ldl...
<p>(A) Western blot of liver lysates taken from negative siRNA or APLP2 siRNA treated mice showing r...
The proprotein convertase PCSK9, a target for the treatment of hypercholesterolemia, is a negative r...
The proprotein convertase PCSK9, a target for the treatment of hypercholesterolemia, is a negative r...
<p>(A and B) Western blot showing APLP2, PCSK9, or Transferrin receptor (TFNR) levels in input fract...
The proprotein convertase PCSK9, a target for the treatment of hypercholesterolemia, is a negative r...
The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is involved in the post-transcription...
<p><b>A</b>) PCSK9 transfection. HEK293 cells were transfected with PCSK9-V5 or empty control pIRES-...
<p>(A) HepG2 cells transfected with LDLR-EGFP were incubated 5h with conditioned media obtained from...
<p><b>A</b>) Chimeric PCSK9 constructs. Schematic representation of PCSK9 and its CHRD coupled to th...
<p><b>A</b>) Generation of chimeric truncated LDLR-V5 constructs. Schematic representation of the LD...
<p><b>A</b>) and <b>C</b>) Secreted Fc (human IgG1 fragment crystallizable region), Fcpro (Fc fused ...
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) post-transcriptionally degrades th...
PCSK9 is a secreted ligand and negative post-translational regulator of low-density lipoprotein rece...
The discovery that proprotein convertase subtilisin/kexin type 9 (PCSK9) mediates degradation of low...
<p>(A) PCSK9 further reduced LPS uptake in Ldlr-/- cells. Primary hepatocytes were isolated from Ldl...
<p>(A) Western blot of liver lysates taken from negative siRNA or APLP2 siRNA treated mice showing r...
The proprotein convertase PCSK9, a target for the treatment of hypercholesterolemia, is a negative r...
The proprotein convertase PCSK9, a target for the treatment of hypercholesterolemia, is a negative r...
<p>(A and B) Western blot showing APLP2, PCSK9, or Transferrin receptor (TFNR) levels in input fract...
The proprotein convertase PCSK9, a target for the treatment of hypercholesterolemia, is a negative r...
The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is involved in the post-transcription...